Literature DB >> 20157372

Possible role of matrix metalloproteinase in osteolytic intracranial meningiomas.

Hyung-Sik Moon1, Shin Jung, Tae-Young Jung, Van Thang Cao, Kyung-Sub Moon, In-Young Kim.   

Abstract

OBJECTIVE: Abnormalities of the bone are frequently encountered in patients with meningioma, and hyperostosis and endostosis are common bone alterations in these tumors. Extensive bony destruction is very unusual in patients with meningioma. We report six cases of intracranial meningioma associated with an osteolytic lesion of the skull and discuss the underlying mechanisms that may be responsible for bone destruction in patients with meningioma.
METHODS: Six patients were classified into three groups, severe, moderate and mild, according to the degree of osteolytic bony destruction. The tumor was classified as intracranial or extracranial, depending on its location. We investigated the potential role of matrix metalloproteinase (MMP) in meningioma-associated osteolysis. The levels of MMP expression were determined by gelatin zymography, reverse transcription-quantitative PCR analysis (RT-PCR) and immunohistochemical analysis.
RESULTS: Complete surgical removal of the lesion was performed in each patient. Histological examination revealed benign meningioma in four cases, and two cases of atypical meningioma. Patients did not have a poor prognosis except one case of recurred atypical meningioma. Gelatin zymography and RT-PCR detected high levels of MMP-2 in almost all extracranial masses in comparison with the intracranial masses and MMP-9 in two. There was no difference in the severity of bone destruction. Immunohistochemical analysis revealed MMP-2 expression in the vicinity of the bone destruction, and a few MMP-9-positive stainings were observed.
CONCLUSION: Osteolysis of the skull in patients with meningiomas might not be indicative of malignant pathological features and poor prognosis. Invasion to the extracranial portion and osteolysis might be associated with MMP-2 expression in meningioma.

Entities:  

Keywords:  Matrix metalloproteinase; Meningioma; Osteolytic

Year:  2010        PMID: 20157372      PMCID: PMC2817509          DOI: 10.3340/jkns.2010.47.1.11

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  23 in total

Review 1.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

2.  Secretion of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by meningiomas detected by cell immunoblot analysis.

Authors:  T Mizoue; H Kawamoto; K Arita; A Tominaga; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

3.  Prognosis in meningioma through evaluation of skull bone patterns.

Authors:  W W Olmsted; T P McGee
Journal:  Radiology       Date:  1977-05       Impact factor: 11.105

4.  Intracranial osteolytic malignant meningiomas appearing as extracranial soft-tissue masses.

Authors:  G Younis; R Sawaya
Journal:  Neurosurgery       Date:  1992-06       Impact factor: 4.654

5.  Primary intraosseous meningiomas of the skull.

Authors:  L Changhong; C Naiyin; G Yuehuan; Z Lianzhong
Journal:  Clin Radiol       Date:  1997-07       Impact factor: 2.350

6.  Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema.

Authors:  A C Nordqvist; H Smurawa; T Mathiesen
Journal:  J Neurosurg       Date:  2001-11       Impact factor: 5.115

7.  An osteolytic meningioma en plaque of the sphenoid ridge.

Authors:  Jin-Uk Baek; Young-Dae Cho; Jae-Chul Yoo
Journal:  J Korean Neurosurg Soc       Date:  2008-01-20

8.  Expression of MMP-2 and -9 in short-term cultures of meningioma: influence of histological subtype.

Authors:  Harcharan K Rooprai; Timothy E van Meter; Susan D F Robinson; Andrew King; Garry J Rucklidge; Geoffrey J Pilkington
Journal:  Int J Mol Med       Date:  2003-12       Impact factor: 4.101

9.  Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.

Authors:  Bent Winding; Róisín NicAmhlaoibh; Henriette Misander; Pernille Høegh-Andersen; Thomas Levin Andersen; Claus Holst-Hansen; Anne-Marie Heegaard; Niels Taekker Foged; Nils Brünner; Jean-Marie Delaissé
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

10.  Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.

Authors:  J H Hur; M J Park; I C Park; D H Yi; C H Rhee; S I Hong; S H Lee
Journal:  J Korean Med Sci       Date:  2000-06       Impact factor: 2.153

View more
  5 in total

Review 1.  Meningioma Tumor Microenvironment.

Authors:  Sajad Sahab-Negah; Ali Gorji
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Proteins involved in regulating bone invasion in skull base meningiomas.

Authors:  Fateme Salehi; Shahrzad Jalali; Ryan Alkins; Joon-Il Lee; Shelly Lwu; Kelly Burrell; Fred Gentili; Sidney Croul; Gelareh Zadeh
Journal:  Acta Neurochir (Wien)       Date:  2012-12-13       Impact factor: 2.216

3.  Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.

Authors:  Takeo Anda; Masaru Honda; Tokuhiro Ishihara; Toshiaki Kamei
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-08       Impact factor: 1.742

4.  Gene Expression of Matrix Metalloproteinases and their Inhibitors (TIMPs) in Meningiomas of Dogs.

Authors:  M T Mandara; A Reginato; G Foiani; S De Luca; G Guelfi
Journal:  J Vet Intern Med       Date:  2017-09-05       Impact factor: 3.333

5.  Cerebral meningioma associated with extensive calvarium osteolysis and presumed intratumoral carcinoma metastasis in a cat.

Authors:  Alice Dussaux; Eymeric Gomes; Murielle Hurion; Elise Rattez; Vincent Mayousse
Journal:  JFMS Open Rep       Date:  2022-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.